Opstapelen schreef op 23 april 2021 08:20:
en dit is volgens mij de absolute potentiële money cow
PathFlow® SARS-CoV-2 Antigen is a professional and home use LFT for the detection
of SARS-CoV-2 antigens using non-invasive anterior nasal swab samples to provide a
result in approximately 15 minutes. Novacyt has been working with a partner to develop
this test, which is able to detect the virus regardless of current known mutations. The
Company intends to launch the test as CE-IVD before the end of Q2 2021 and expects it
to complement Novacyt’s established position in COVID-19 PCR testing. As the market for
COVID-19 testing continues to develop, the Directors believe this product could add
significant revenues for Novacyt